{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:49:06Z","timestamp":1790938146451,"version":"4.1.0"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170188"],"award-info":[{"award-number":["82170188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Genetic alterations of chronic active B-cell receptor signaling often occur in primary central nervous system lymphoma (PCNSL). We conducted a phase II trial of high-dose methotrexate plus ibrutinib and temozolomide in the treatment of newly diagnosed PCNSL. A total of 35 patients were enrolled, with 33 patients included in the analysis. The best overall response rate was 93.9%, and the complete response rate was 72.7% for induction therapy. The 2-year progression-free survival and overall survival were 57.6% (95% confidence interval, 49.0%\u201366.2%) and 84.8% (95% confidence interval, 78.6%\u201391.0%). The incidence of grade \u2265 3 adverse events was 27.3% (10 of 33). Mutations in PIM1, MYD88, BTG2, and CD79B were most frequent among 475 genes tested by targeted sequencing of tumor and cerebrospinal fluid (CSF) samples at baseline. The consistency of ctDNA clearance from CSF\/plasma and complete response on imaging were observed. Patients with clearance of ctDNA from CSF after two cycles achieved longer progression-free survival (P = 0.044).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We report promising efficacy and good tolerability of Bruton tyrosine kinase (BTK) inhibitor ibrutinib in treatment of newly diagnosed PCNSL. Additionally, we explored the contribution of ctDNA profiling to predictive potential in this prospective study. The consistency of ctDNA clearance from CSF\/plasma was associated with more sustained treatment response and survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0156","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T11:41:01Z","timestamp":1738842061000},"page":"191-202","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-2999","authenticated-orcid":false,"given":"Yan","family":"Gao","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1270-2343","authenticated-orcid":false,"given":"Liqin","family":"Ping","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."},{"name":"2Department of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-4670","authenticated-orcid":false,"given":"Changguo","family":"Shan","sequence":"additional","affiliation":[{"name":"3Guangdong Sanjiu Brain Hospital, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-434X","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-5051","authenticated-orcid":false,"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"4Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4564-1139","authenticated-orcid":false,"given":"Mingyao","family":"Lai","sequence":"additional","affiliation":[{"name":"3Guangdong Sanjiu Brain Hospital, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-467X","authenticated-orcid":false,"given":"Linbo","family":"Cai","sequence":"additional","affiliation":[{"name":"3Guangdong Sanjiu Brain Hospital, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8591-1597","authenticated-orcid":false,"given":"Bing","family":"Bai","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-6293","authenticated-orcid":false,"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-1654","authenticated-orcid":false,"given":"Haoqing","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0483-7094","authenticated-orcid":false,"given":"Xiaoyu","family":"Hong","sequence":"additional","affiliation":[{"name":"5Nanjing Geneseeq Technology Inc., Nanjing, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-263X","authenticated-orcid":false,"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-1907","authenticated-orcid":false,"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2026041309333236200_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041309333236200_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2026041309333236200_bib3","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1","article-title":"Pathology with clinical correlations of primary central nervous system non-Hodgkin\u2019s lymphoma. The Massachusetts General Hospital experience 1958-1989","volume":"74","author":"Miller","year":"1994","journal-title":"Cancer"},{"key":"2026041309333236200_bib5","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"2026041309333236200_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"2026041309333236200_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br J Cancer"},{"key":"2026041309333236200_bib8","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026041309333236200_bib10","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"2026041309333236200_bib11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"2026041309333236200_bib12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neo.2018.08.012","article-title":"Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes","volume":"20","author":"Zhou","year":"2018","journal-title":"Neoplasia"},{"key":"2026041309333236200_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"28","author":"Kraan","year":"2014","journal-title":"Leukemia"},{"key":"2026041309333236200_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"2026041309333236200_bib15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"2026041309333236200_bib16","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026041309333236200_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026041309333236200_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026041309333236200_bib20","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"key":"2026041309333236200_bib21","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib23","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.ctrv.2020.102106","article-title":"Liquid biopsy in lymphoma: molecular methods and clinical applications","volume":"91","author":"Cirillo","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026041309333236200_bib24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00277-019-03821-9","article-title":"Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases","volume":"99","author":"Yuan","year":"2020","journal-title":"Ann Hematol"},{"key":"2026041309333236200_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jocn.2020.11.031","article-title":"GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas","volume":"83","author":"Marcus","year":"2021","journal-title":"J Clin Neurosci"},{"key":"2026041309333236200_bib27","doi-asserted-by":"crossref","first-page":"100323","DOI":"10.1016\/j.modpat.2023.100323","article-title":"Genomic profiling of primary diffuse large B-cell lymphoma of the central nervous system suggests novel potential therapeutic targets","volume":"36","author":"Agostinelli","year":"2023","journal-title":"Mod Pathol"},{"key":"2026041309333236200_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Bro\u00ebt","year":"2006","journal-title":"Blood"},{"key":"2026041309333236200_bib29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041309333236200_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"2026041309333236200_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"2026041309333236200_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","article-title":"ATRX, a guardian of chromatin","volume":"39","author":"Aguilera","year":"2023","journal-title":"Trends Genet"},{"key":"2026041309333236200_bib33","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41467-022-31194-7","article-title":"The chromatin remodeller ATRX facilitates diverse nuclear processes, in a stochastic manner, in both heterochromatin and euchromatin","volume":"13","author":"Truch","year":"2022","journal-title":"Nat Commun"},{"key":"2026041309333236200_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.celrep.2015.03.036","article-title":"ATRX plays a key role in maintaining silencing at interstitial heterochromatic loci and imprinted genes","volume":"11","author":"Voon","year":"2015","journal-title":"Cell Rep"},{"key":"2026041309333236200_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2023-187650","article-title":"Prognostic utility of minimal residual disease (MRD) after curative intent induction therapy for DLBCL: a prospective real-world ctdna study","volume":"142","author":"Sworder","year":"2023","journal-title":"Blood"},{"key":"2026041309333236200_bib36","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2023-173953","article-title":"Glofitamab (glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: preliminary safety and efficacy results","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2026041309333236200_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/blood-2023-181007","article-title":"Circulating tumor DNA dynamics as early outcome predictors for lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma from the phase 3 TRANSFORM study","volume":"142","author":"Stepan","year":"2023","journal-title":"Blood"},{"key":"2026041309333236200_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2023-173708","article-title":"Long-term remissions with MRD-guided acalabrutinib, venetoclax and obinutuzumab in relapsed\/refractory CLL: follow-up efficacy and circulating tumor DNA analysis of the CLL2-baag trial","volume":"142","author":"Furstenau","year":"2023","journal-title":"Blood"},{"key":"2026041309333236200_bib39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2023-181666","article-title":"Clinical implications of CSF-ctdna in CNS involvement of newly diagnosed diffuse large B cell lymphoma: an improvement of diagnosis, treatment and evaluation","volume":"142","author":"Liang","year":"2023","journal-title":"Blood"},{"key":"2026041309333236200_bib40","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"2026041309333236200_bib41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"2026041309333236200_bib42","first-page":"2489","article-title":"The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma","volume":"6","author":"Kuo","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2026041309333236200_bib43","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib44","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00277-023-05292-5","article-title":"PD-1 blockade combined with ICE regimen in relapsed\/refractory diffuse large B-cell lymphoma","volume":"102","author":"Ping","year":"2023","journal-title":"Ann Hematol"},{"key":"2026041309333236200_bib45","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","article-title":"A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas","volume":"107","author":"Wang","year":"2022","journal-title":"Haematologica"},{"key":"2026041309333236200_bib46","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"2026041309333236200_bib47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nmeth.2883","article-title":"PyClone: statistical inference of clonal population structure in cancer","volume":"11","author":"Roth","year":"2014","journal-title":"Nat Methods"},{"key":"2026041309333236200_bib48","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"2026041309333236200_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026041309333236200_bib50","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026041309333236200_bib51","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026041309333236200_bib52","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"2026041309333236200_bib53","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","article-title":"Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly","volume":"22","author":"Fritsch","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0156\/3540007\/bcd-24-0156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0156\/3563451\/bcd-24-0156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/191\/3601240\/bcd-24-0156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/191\/3601240\/bcd-24-0156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:33:42Z","timestamp":1776087222000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/191\/762115\/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0156","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.28929706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929688","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929685","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929691","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929715","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7801753","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}